Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Kathryn C. Arbour, Tanvetyanon Tawee, Rona Yaeger, Aparna R. Parikh, Paul Oberstein, Kyriakos P. Papadopoulos, John Strickler, Alexander Spira, John Powderly, Minal Barve, Judy Wang, Jia Luo, Nilofer Saba Hazad, Alexander Starodub, Patricia LoRusso, Avantika Elgin, Michelle Yang, Walter Yu, Mark McCleland, Satwant Lally, Sophia Sohoni, David S. Hong
Institutions: Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, Harvard University, Massachusetts General Hospital, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, South Texas Accelerated Research Therapeutics, Duke University, Duke Medical Center, Virginia Cancer Specialists, Carolina BioOncology Institute, Mary Crowley Cancer Research Center, Florida Cancer Specialists & Research Institute, Dana-Farber Cancer Institute, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Christ Hospital, Yale University, Revolution Medicines (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410596274